Integra LifeSciences Names Keith Valentine as Chief Executive Officer of SeaSpine; John Bostjancic Appointed as Chief Financial Officer of SeaSpine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Integra LifeSciences (IART) Appoints New CEO
April 30, 2015 4:28 PM EDTIntegra LifeSciences (NASDAQ: IART) announced the appointment, effective May 1, 2015, of Keith Valentine as Chief Executive Officer of SeaSpine Holdings Corporation, which will be an independent, publicly traded company following the completion of its spin-off from Integra. SeaSpine, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, located in Vista, CA, has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions.
"With more than 20 years of experience in the orthopedic industry and an outstanding track record of success, Keith's proven leadership skills will drive growth and innovation at... More
Integra LifeSciences (IART) Tops Q1 EPS by 13c
April 30, 2015 4:27 PM EDTIntegra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.76, $0.13 better than the analyst estimate of $0.63. Revenue for the quarter came in at $233.7 million versus the consensus estimate of $229.69 million.
Integra LifeSciences sees FY2015 EPS of $3.15-$3.33, versus the consensus of $3.17. Integra LifeSciences sees FY2015... More



